Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF): 2014-2025

Historic Depreciation & Amortization (CF) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $110,000.

  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) fell 15.38% to $110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $463,000, marking a year-over-year decrease of 18.34%. This contributed to the annual value of $540,000 for FY2024, which is 3.45% up from last year.
  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) amounted to $110,000 in Q3 2025, which was down 2.65% from $113,000 recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) peaked at $150,000 during Q4 2023, and registered a low of $25,000 during Q2 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $130,000 (2024), whereas its average is $127,455.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) plummeted by 60.94% in 2021 and then soared by 340.62% in 2022.
  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) (Quarterly) stood at $32,000 in 2021, then spiked by 340.62% to $141,000 in 2022, then climbed by 6.38% to $150,000 in 2023, then dropped by 18.00% to $123,000 in 2024, then declined by 15.38% to $110,000 in 2025.
  • Its Depreciation & Amortization (CF) was $110,000 in Q3 2025, compared to $113,000 in Q2 2025 and $117,000 in Q1 2025.